Health
Experimental GLS-1 inhibitor demonstrates antitumor activity in advanced treatment-resistant ovarian cancer
Headline as filed by Medical Xpress.
Compare coverage — 1 report
| Publisher | Headline | Summary | Published | Detected | Delay | Source | Status |
|---|---|---|---|---|---|---|---|
| Medical Xpress | Experimental GLS-1 inhibitor demonstrates antitumor activity in advanced treatment-resistant ovarian cancer |
Combining the experimental therapy IACS-6274 with targeted therapy bevacizumab and paclitaxel chemotherapy showed promising antitumor activity in a Phase I trial of patients with advanced platinum-res |
0m | medicalxpress.com | First |
Headlines and summaries belong to the publisher named beside them. “Published” is what their feed stated; “detected” is when PageNews first held the report. Delay is measured from the earliest report on this event and describes timing only.
Reader comments
Comments are written by readers. PageNews does not check them and does not stand behind them, and a name here is a name someone typed, not a person we have identified.
Nobody has commented on this story yet.